183 related articles for article (PubMed ID: 33324721)
1. Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.
Duffy J; Marquez P; Dores GM; Ng C; Su J; Cano M; Perez-Vilar S
Open Forum Infect Dis; 2020 Dec; 7(12):ofaa516. PubMed ID: 33324721
[TBL] [Abstract][Full Text] [Related]
2. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.
Perez-Vilar S; Dores GM; Marquez PL; Ng CS; Cano MV; Rastogi A; Lee L; Su JR; Duffy J
Vaccine; 2022 Jan; 40(2):247-254. PubMed ID: 34887130
[TBL] [Abstract][Full Text] [Related]
3. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
4. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
Patton ME; Stephens D; Moore K; MacNeil JR
MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
[TBL] [Abstract][Full Text] [Related]
5. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
Myers TR; McNeil MM; Ng CS; Li R; Lewis PW; Cano MV
Vaccine; 2017 Mar; 35(14):1758-1763. PubMed ID: 28262331
[TBL] [Abstract][Full Text] [Related]
6. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
Burman C; Alderfer J; Snow VT
J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
[TBL] [Abstract][Full Text] [Related]
7. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
[TBL] [Abstract][Full Text] [Related]
8. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
Miller ER; Moro PL; Cano M; Lewis P; Bryant-Genevier M; Shimabukuro TT
Vaccine; 2016 May; 34(25):2841-6. PubMed ID: 27087150
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020.
Stefanizzi P; Bianchi FP; Martinelli A; Di Lorenzo A; De Petro P; Graziano G; Lattanzio S; Diella G; Stella P; Ancona D; Tafuri S
Hum Vaccin Immunother; 2022 Dec; 18(1):2041359. PubMed ID: 35201942
[TBL] [Abstract][Full Text] [Related]
11. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
[TBL] [Abstract][Full Text] [Related]
12. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Beeslaar J; Mather S; Absalon J; Eiden JJ; York LJ; Crowther G; Maansson R; Maguire JD; Peyrani P; Perez JL
Vaccine; 2022 Mar; 40(12):1872-1878. PubMed ID: 35164991
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
14. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
15. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
Shirley M; Taha MK
Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
[TBL] [Abstract][Full Text] [Related]
16. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
[TBL] [Abstract][Full Text] [Related]
17. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
[TBL] [Abstract][Full Text] [Related]
19. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
20. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
